| Literature DB >> 28328963 |
Charat Thongprayoon1,2, Wisit Cheungpasitporn1, Zhen Cheng1,3, Qi Qian1.
Abstract
Serum Cl (sCl) alterations in hospitalized patients have not been comprehensively studied in recent years. The aim of this study is to investigate the prevalence and outcome significance of (1) sCl alterations on hospital admission, and (2) sCl evolution within the first 48 hr of hospital admission. We conducted a retrospective study of all hospital admissions in the years 2011-2013 at Mayo Clinic Rochester, a 2000-bed tertiary medical center. Outcome measures included hospital mortality, length of hospital stay and discharge disposition. 76,719 unique admissions (≥18 years old) were studied. Based on hospital mortality, sCl in the range of 105-108 mmol/L was found to be optimal. sCl <100 (n = 13,611) and >108 (n = 11,395) mmol/L independently predicted a higher risk of hospital mortality, longer hospital stay and being discharged to a care facility. 13,089 patients (17.1%) had serum anion gap >12 mmol/L; their hospital mortality, when compared to 63,630 patients (82.9%) with anion gap ≤12 mmol/L, was worse. Notably, patients with elevated anion gap displayed a progressively worsening mortality with rising sCl. sCl elevation within 48 hr of admission was associated with a higher proportion of 0.9% saline administration and was an independent predictor for hospital mortality. Moreover, the magnitude of sCl rise was inversely correlated to the days of patient survival. In conclusion, serum Cl alterations on admission predict poor clinical outcomes. Post-admission sCl increase, due to Cl-rich fluid infusion, independently predicts hospital mortality. These results raise a critical question of whether iatrogenic cause of hyperchloremia should be avoided, a question to be addressed by future prospective studies.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28328963 PMCID: PMC5362234 DOI: 10.1371/journal.pone.0174430
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1The study flow chart.
Fig 2Hospital mortality analyzed by restricted cubic spline.
Baseline clinical characteristics.
| Variables | All | Admission serum chloride level (mmol/L) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| <95 | 95–100 | 100–105 | 105–108 | 108–113 | 113–118 | >118 | p | ||
| N | 76,719 | 3,360 | 10,251 | 33,647 | 18,066 | 9,656 | 1,490 | 249 | |
| Age (year) | 61.1±17.8 | 66±16 | 64±17 | 60±18 | 60±18 | 61±18 | 61±17 | 62±19 | <0.001 |
| Male | 40,515 (53) | 1,602 (48) | 5,498 (54) | 18,519 (55) | 9,190 (51) | 4,864 (50) | 717 (48) | 125 (50) | <0.001 |
| Caucasian | 71,229 (93) | 3,136 (93) | 9,483 (93) | 31,319 (93) | 16,762 (93) | 8,956 (93) | 1,348 (90) | 225 (90) | |
| Principal Diagnosis
Cardiovascular Endocrine/Metabolic Gastrointestinal Renal Disease Hematology/Oncology Infectious Disease Respiratory Injury/poisoning Other | <0.001 | ||||||||
| Charlson Score | 1.8±2.3 | 2.5±2.7 | 2.3±2.6 | 1.7±2.3 | 1.6±2.2 | 1.6±2.2 | 1.6±2.2 | 1.8±2.3 | <0.001 |
| eGFR (ml/min/1.73m2) | 78.3±28.4 | 69±33 | 74±31 | 80±27 | 80±27 | 76±29 | 74±32 | 69±39 | <0.001 |
| Na (mmol/L) | 138.0±4.0 | 129.1±5.9 | 134.8±3.4 | 137.9±2.7 | 139.6±2.5 | 140.6±2.7 | 142.3±3.5 | 145.6±7.8 | <0.001 |
| K (mmol/L) | 4.2±0.6 | 4.2±0.8 | 4.2±0.6 | 4.3±0.5 | 4.2±0.5 | 4.2±0.6 | 4.1±0.7 | 3.8±1.1 | <0.001 |
| HCO3 (mmol/L) | 25.2±3.6 | 27.0±5.5 | 26.4±3.9 | 25.7±3.0 | 24.7±2.9 | 23.0±3.2 | 21.0±3.6 | 19.0±5.8 | <0.001 |
| DiffNa-Cl (mmol/L) | 34.8±3.7 | 38.6±5.1 | 37.3±3.3 | 35.6±2.6 | 33.7±2.5 | 31.3±2.8 | 28.1±3.5 | 24.1±6.7 | <0.001 |
| Cl: Na ratio | 0.75±0.03 | 0.70±0.03 | 0.72±0.02 | 0.74±0.01 | 0.76±0.01 | 0.78±0.02 | 0.80±0.02 | 0.84±0.04 | <0.001 |
| Anion Gap (mmol/L) | 9.6±3.4 | 11.6±4.9 | 10.8±3.6 | 9.9±3.1 | 9.0±3.0 | 8.3±3.3 | 7.0±4.1 | 5.1±6.9 | <0.001 |
| Albumin (g/dL), n = 10,576 | 3.5±0.7 | 3.4±0.7 | 3.5±0.7 | 3.6±0.7 | 3.6±0.7 | 3.4±0.7 | 3.1±0.7 | 3.0±0.8 | <0.001 |
Continuous data are presented as mean ± SD; categorical data are presented as count (%)
Fig 3Hospital mortality in percentage (%) among patients with various admission Cl levels.
Clinical outcomes.
| Outcome | Admission serum chloride level (mmol/L) | ||||||
|---|---|---|---|---|---|---|---|
| <95 | 95–100 | 100–105 | 105–108 | 108–113 | 113–118 | >118 | |
| Hospital mortality | 127 (3.8) | 226 (2.2) | 355 (1.1) | 164 (0.9) | 164 (1.7) | 53 (3.6) | 24 (9.6) |
| Mortality, OR (95%CI) | |||||||
| Model 1: unadjusted | 4.29 (3.39–5.42) | 2.46 (2.01–3.02) | 1.16 (0.97–1.40) | 1 (ref) | 1.89 (1.52–2.35) | 4.03 (2.91–5.47) | 11.64 |
| Model 2 | 2.63 (2.06–3.34) | 1.66 (1.35–2.05) | 1.11 (0.92–1.35) | 1 (ref) | 1.61 (1.29–2.01) | 2.96 (2.12–4.05) | 6.34 |
| Model 3: Model 2 and Na | 2.14 (1.59–2.87) | 1.51 (1.21–1.89) | 1.08 (0.89–1.30) | 1 (ref) | 1.65 (1.32–2.06) | 3.14 (2.25–4.32) | 7.26 |
| Hospital LOS | 5 (3–9) | 5 (3–8) | 4 (3–6) | 4 (3–7) | 5 (3–7) | 6 (5–9) | 6 (4–12) |
| LOS, relative prolongation | |||||||
| Model 1: unadjusted | 1.28 (1.25–1.32) | 1.13 (1.11–1.15) | 0.98 (0.97–0.99) | 1 (ref) | 1.15 (1.13–1.17) | 1.45 (1.40–1.50) | 1.53 (1.40–1.67) |
| Model 2 | 1.25 (1.22–1.29) | 1.11 (1.09–1.12) | 0.98 (0.97–1.002) | 1 (ref) | 1.13 (1.11–1.15) | 1.39 (1.34–1.45) | 1.45 (1.33–1.58) |
| Model 3: Model 2 and Na | 1.29 (1.26–1.34) | 1.12 (1.10–1.14) | 0.99 (0.97–1.01) | 1 (ref) | 1.12 (1.10–1.14) | 1.39 (1.33–1.43) | 1.42 (1.31–1.55) |
| Hospital survivor (n = 75,606) | 3,233 | 10,025 | 33,292 | 17,902 | 9,492 | 1,437 | 225 |
| Discharge disposition | |||||||
| - Home | 2,203 (68) | 7,398 (74) | 27,123 (81) | 14,590 (81) | 7,558 (80) | 1,072 (75) | 139 (62) |
| - Home Health Care | 305 (9) | 856 (9) | 1,897 (6) | 994 (6) | 568 (6) | 96 (7) | 12 (5) |
| - In-hospital rehab | 13 (0.4) | 45 (0.4) | 91 (0.3) | 75 (0.4) | 36 (0.4) | 12 (0.9) | 1 (0.4) |
| - Skilled Nursing facility | 686 (21) | 1,680 (17) | 4,066 (12) | 2,191 (12) | 1,299 (14) | 247 (17) | 69 (31) |
| - Swing bed | 26 (0.8) | 46 (0.4) | 115 (0.3) | 52 (0.3) | 31 (0.3) | 10 (0.7) | 4 (2) |
| Discharge to short or long term care facility, OR (95% CI) | |||||||
| Model 1: unadjusted | 1.94 (1.77–2.13) | 1.44 (1.35–1.54) | 0.99 (0.94–1.04) | 1 (ref) | 1.13 (1.05–1.21) | 1.55 (1.34–1.78) | 3.29 (2.47–4.35) |
| Model 2 | 1.46 (1.31–1.62) | 1.16 (1.08–1.26) | 0.97 (0.92–1.03) | 1 (ref) | 1.16 (1.08–1.26) | 1.89 (1.61–2.20) | 3.53 (2.53–4.88) |
| Model 3: Model 2 and Na | 1.48 (1.30–1.69) | 1.18 (1.08–1.28) | 0.98 (0.92–1.04) | 1 (ref) | 1.16 (1.07–1.26) | 1.88 (1.60–2.19) | 3.49 (2.50–4.85) |
#model 2: Adjusted for age, sex, Charlson comorbidities score, eGFR and principal diagnosis.
+discharge to short or long term care facility
Baseline clinical characteristics of patients with AG ≤ 12.
| Variables | All | Admission serum chloride level (mmol/L) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| <95 | 95–100 | 100–105 | 105–108 | 108–113 | 113–118 | >118 | p | ||
| N | 63,630 | 2,178 | 7,368 | 27,742 | 15,985 | 8,755 | 1,380 | 222 | |
| Age (year) | 61.4±17.7 | 69±15 | 65±17 | 61±18 | 60±18 | 61±18 | 61±17 | 62±19 | <0.001 |
| Male | 33,483 (53) | 998 (46) | 3,922 (53) | 15,291 (55) | 8,113 (51) | 4,384 (50) | 662 (48) | 113 (51) | <0.001 |
| Caucasian | 59,199 (93) | 2,044 (94) | 6,859 (93) | 25,862 (93) | 14,852 (93) | 8,127 (93) | 1,254 (91) | 201 (91) | 0.01 |
| Principal Diagnosis
Cardiovascular Endocrine/Metabolic Gastrointestinal Renal Disease Hematology/Oncology Infectious Disease Respiratory Injury/poisoning Other | <0.001 | ||||||||
| Charlson Score | 1.8±2.3 | 2.5±2.7 | 2.3±2.7 | 1.7±2.3 | 1.6±2.2 | 1.6±2.2 | 1.6±2.2 | 1.7±2.2 | <0.001 |
| eGFR (ml/min/1.73m2) | 79.8±26.8 | 74±29 | 76±29 | 82±26 | 81±26 | 78±28 | 76±30 | 73±38 | <0.001 |
| Na (mmol/L) | 137.8±3.8 | 128.1±5.8 | 134.3±3.3 | 137.6±2.6 | 139.3±2.4 | 140.4±2.5 | 142.0±3.2 | 144.7±7.1 | <0.001 |
| K (mmol/L) | 4.2±0.5 | 4.2±0.7 | 4.2±0.6 | 4.3±0.5 | 4.2±0.5 | 4.2±0.5 | 4.1±0.7 | 3.8±1.1 | <0.001 |
| HCO3 (mmol/L) | 25.7±3.2 | 28.5±5.1 | 27.5±3.3 | 26.4±2.6 | 25.2±2.6 | 23.4±2.8 | 21.4±3.2 | 19.5±5.5 | <0.001 |
| DiffNa-Cl (mmol/L) | 34.3±3.4 | 37.5±4.8 | 36.7±3.1 | 35.3±2.5 | 33.5±2.4 | 31.0±2.7 | 27.8±3.2 | 23.2±6.1 | <0.001 |
| Cl: Na ratio | 0.75±0.02 | 0.71±0.03 | 0.73±0.02 | 0.74±0.01 | 0.76±0.01 | 0.78±0.02 | 0.80±0.02 | 0.84±0.04 | <0.001 |
| Anion Gap (mmol/L) | 8.5±2.4 | 8.9±2.5 | 9.2±2.2 | 8.9±2.2 | 8.3±2.3 | 7.6±2.6 | 6.4±3.4 | 3.7±5.9 | <0.001 |
| Albumin (g/dL), n = 7,866 | 3.5±0.7 | 3.3±0.6 | 3.4±0.7 | 3.6±0.7 | 3.6±0.7 | 3.4±0.7 | 3.1±0.7 | 2.9±0.8 | <0.001 |
Continuous data are presented as mean±SD; categorical data are presented as count (%)
Baseline clinical characteristics of patients with AG > 12.
| Variables | All | Admission serum chloride level (mmol/L) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| <95 | 95–100 | 100–105 | 105–108 | 108–113 | 113–118 | >118 | p | ||
| N | 13,089 | 1,182 | 2,883 | 5,905 | 2,081 | 901 | 110 | 27 | |
| Age (year) | 59.8±18.2 | 62±17 | 61±18 | 59±18 | 59±19 | 61±19 | 61±19 | 67±20 | <0.001 |
| Male | 7,032 (54) | 604 (51) | 1,576 (55) | 3,228 (55) | 1,077 (52) | 480 (53) | 55 (50) | 12 (44) | 0.08 |
| Caucasian | 12,030 (92) | 1,092 (92) | 2,624 (91) | 5,457 (92) | 1,910 (92) | 829 (92) | 94 (85) | 24 (89) | |
| Principal Diagnosis
Cardiovascular Endocrine/Metabolic Gastrointestinal Renal Disease Hematology/Oncology Infectious Disease Respiratory Injury/poisoning Other | <0.001 | ||||||||
| Charlson Score | 1.9±2.4 | 2.5±2.8 | 2.2±2.6 | 1.7±2.2 | 1.8±2.3 | 2.0±2.4 | 1.9±2.5 | 2.1±2.4 | <0.001 |
| eGFR (ml/min/1.73m2) | 70.7±34.2 | 58±37 | 69±36 | 75±32 | 73±32 | 62±36 | 51±37 | 37±30 | <0.001 |
| Na (mmol/L) | 138.6±4.5 | 131.0±5.5 | 136.3±3.2 | 139.4±2.7 | 141.4±2.6 | 142.9±3.3 | 145.6±5.1 | 153.3±8.7 | <0.001 |
| K (mmol/L) | 4.3±0.7 | 4.3±0.9 | 4.3±0.7 | 4.3±0.6 | 4.3±0.6 | 4.2±0.8 | 4.1±1.0 | 3.9±0.8 | <0.001 |
| HCO3 (mmol/L) | 22.5±3.9 | 24.3±5.2 | 23.7±3.8 | 22.8±3.1 | 21.1±3.0 | 18.9±3.7 | 16.0±4.8 | 15.0±6.4 | <0.001 |
| DiffNa-Cl (mmol/L) | 37.4±3.6 | 40.8±4.9 | 38.9±3.1 | 37.3±2.6 | 35.6±2.6 | 33.6±3.2 | 31.3±4.9 | 31.3±7.1 | <0.001 |
| Cl: Na ratio | 0.73±0.03 | 0.69±0.03 | 0.72±0.02 | 0.73±0.01 | 0.75±0.01 | 0.77±0.02 | 0.79±0.03 | 0.80±0.04 | <0.001 |
| Anion Gap (mmol/L) | 14.9±2.6 | 16.5±4.3 | 15.1±2.8 | 14.6±2.1 | 14.5±2.0 | 14.7±2.3 | 15.2±2.7 | 16.3±3.6 | <0.001 |
| Albumin (g/dL), n = 2,710 | 3.6±0.7 | 3.5±0.8 | 3.6±0.6 | 3.8±0.6 | 3.7±0.7 | 3.4±0.7 | 3.4±0.7 | 3.2±0.8 | <0.001 |
Continuous data are presented as mean±SD; categorical data are presented as count (%)
Fig 4Hospital mortality in percentage (%) among patients with AG ≤12 and >12 mmol/L with various admission Cl levels.
Hospital mortality in patients with AG ≤12 or >12 mmol/L and with various serum Cl concentrations.
| Outcome | Admission serum chloride level (mmol/L) | ||||||
|---|---|---|---|---|---|---|---|
| <95 | 95–100 | 100–105 | 105–108 | 108–113 | 113–118 | >118 | |
| AG ≤12 (n = 63,630) | |||||||
| Hospital mortality | 80 (3.7) | 139 (1.9) | 238 (0.9) | 122 (0.8) | 119 (1.4) | 40 (2.9) | 18 (8.1) |
| - Model 1: unadjusted | 4.96 (3.71–6.58) | 2.50 (1.96–3.20) | 1.13 (0.91–1.40) | 1 (ref) | 1.79 (1.39–2.31) | 3.88 (2.67–5.52) | 11.47 |
| - Model 2 | 2.87 (2.13–3.85) | 1.59 (1.24–2.05) | 1.06 (0.85–1.33) | 1 (ref) | 1.55 (1.20–2.00) | 2.96 (2.02–4.24) | 6.76 |
| - Model 3: Model 2 and Na | 1.90 (1.30–2.76) | 1.32 (1.002–1.73) | 0.99 (0.79–1.25) | 1 (ref) | 1.62 (1.25–2.09) | 3.29 (2.24–4.74) | 8.28 |
| AG >12 (n = 13,089) | |||||||
| Hospital mortality | 47 (4.0) | 87 (3.0) | 117 (2.0) | 42 (2.0) | 45 (5.0) | 13 (11.8) | 6 (22.2) |
| - Model 1: unadjusted | 2.01 (1.32–3.08) | 1.51 (1.05–2.21) | 0.98 (0.69–1.42) | 1 (ref) | 2.55 (1.66–3.93) | 6.51 (3.26–12.21) | 13.87 |
| - Model 2 | 1.58 (1.02–2.45) | 1.30 (0.89–1.92) | 1.01 (0.71–1.46) | 1 (ref) | 2.11 (1.36–3.27) | 4.14 (1.99–8.13) | 5.87 |
| - Model 3: Model 2 and Na | 0.92 (0.54–1.56) | 0.99 (0.66–1.50) | 0.91 (0.63–1.32) | 1 (ref) | 2.30 (1.48–3.58) | 5.45 (2.59–10.84) | 11.54 |
#model 2: Adjusted for age, sex, Charlson comorbidities score, eGFR and principal diagnosis.
Baseline characteristics in patients with Cl evolution within 48 hours of hospital admission.
| variables | Change in serum chloride within the first 48 hours of hospital admission (mmol/L) | ||||||
|---|---|---|---|---|---|---|---|
| < -4 | -4 to -2 | -2 to 0 | 0 to 2 | 2 to 4 | >4 | p | |
| N | 5,138 | 6,776 | 11,751 | 12,780 | 9,553 | 9,525 | |
| Age (year) | 60.3±17.1 | 63.3±16.7 | 63.8±16.7 | 63.8±17.1 | 63.9±17.4 | 63.0±17.9 | <0.001 |
| Male | 2,890 (56) | 3,873 (57) | 6,643 (57) | 7,051 (55) | 4,917 (51) | 4,486 (47) | <0.001 |
| Caucasian | 4,739 (92) | 6,331 (93) | 11,004 (94) | 11,940 (93) | 8,868 (93) | 8,785 (92) | <0.001 |
| Principal Diagnosis
Cardiovascular Endocrine/Metabolic Gastrointestinal Renal Disease Hematology/Oncology Infectious Disease Respiratory Injury/poisoning Other | <0.001 | ||||||
| Charlson Score | 1.6±2.2 | 1.9±2.4 | 2.0±2.4 | 2.0±2.4 | 2.0±2.4 | 2.2±2.5 | <0.001 |
| eGFR (ml/min/1.73m2) | 79.0±28.1 | 75.2±28.1 | 74.9 (28.1) | 74.9±28.7 | 74.0±29.5 | 71.1±32.3 | <0.001 |
| Na (mmol/L) | 139.7±3.6 | 139.1±3.4 | 138.6±3.6 | 137.8±3.9 | 137.0±4.1 | 135.2±5.3 | <0.001 |
| HCO3 (mmol/L) | 23.6±3.7 | 24.6±3.6 | 25.1±3.5 | 25.3±3.6 | 25.4±3.8 | 25.0±4.4 | <0.001 |
| Anion Gap (mmol/L) | 7.7±3.8 | 8.9±3.3 | 9.3±3.2 | 9.7±3.3 | 10.1±3.4 | 11.2±4.2 | <0.001 |
| Change in Hemoglobin (g/dL) | -0.8±1.6 | -0.8±1.4 | -0.9±1.3 | -1.0±1.3 | -1.1±1.3 | -1.4±1.4 | <0.001 |
Continuous data are presented as mean±SD; categorical data are presented as count (%)
Hospital mortality in patients with Cl evolution within 48 hours of hospital admission.
| Outcome | Change in serum chloride within the first 48 hours of hospital admission (mmol/L) | |||||
|---|---|---|---|---|---|---|
| < -4 | -4 to -2 | -2 to 0 | 0 to 2 | 2 to 4 | >4 | |
| Hospital Mortality | 68 (1.3) | 78 (1.2) | 155 (1.3) | 178 (1.4) | 179 (1.9) | 305 (3.2) |
| Mortality, OR (95%CI) | ||||||
| - Unadjusted | 1.00 (0.75–1.33) | 0.87 (0.66–1.14) | 1 (ref) | 1.06 (0.85–1.31) | 1.43 (1.15–1.78) | 2.47 (2.04–3.01) |
| - Adjusted | 1.14 (0.85–1.52) | 0.91 (0.68–1.19) | 1 (ref) | 1.03 (0.83–1.28) | 1.33 (1.07–1.66) | 2.10 (1.72–2.58) |
# adjusted for age, sex, Charlson Comorbidities Score, eGFR, principal diagnosis
Hospital mortality in subgroups of patients with various serum Cl levels.
| Outcome (n = 55,523) | Change in serum chloride within the first 48 hours of hospital admission (mmol/L) | |||||
|---|---|---|---|---|---|---|
| < -4 | -4 to -2 | -2 to 0 | 0 to 2 | 2 to 4 | >4 | |
| Serum Cl <105 mmol/L (n = 33,515) | ||||||
| Hospital Mortality | 13 (1.3) | 30 (1.2) | 88 (1.5) | 120 (1.4) | 133 (1.8) | 237 (2.8) |
| Unadjusted OR (95%CI) | 0.85 (0.45–1.47) | 0.84 (0.54–1.25) | 1 (ref) | 0.98 (0.75–1.30) | 1.25 (0.95–1.64) | 1.96 (1.54–2.53) |
| 0.87 (0.46–1.52) | 0.86 (0.56–1.30) | 1 (ref) | 1.00 (0.76–1.33) | 1.24 (0.94–1.64) | 1.84 (1.43–2.39) | |
| Serum Cl 105–108 mmol/L (n = 12,447) | ||||||
| Hospital Mortality | 8 (0.7) | 15 (0.7) | 29 (0.8) | 19 (0.6) | 26 (1.6) | 37 (4.4) |
| Unadjusted OR (95%CI) | 0.89 (0.38–1.85) | 0.83 (0.43–1.53) | 1 (ref) | 0.74 (0.41–1.32) | 2.03 (1.19–3.46) | 5.59 (3.42–9.20) |
| 0.95 (0.40–1.99) | 0.82 (0.43–1.51) | 1 (ref) | 0.69 (0.38–1.23) | 1.80 (1.04–3.10) | 4.35 (2.61–7.31) | |
| Serum Cl >108 mmol/L (n = 9,561) | ||||||
| Hospital Mortality | 47 (1.6) | 33 (1.6) | 38 (1.8) | 39 (3.0) | 20 (3.1) | 31 (9.8) |
| Unadjusted OR (95%CI) | 0.90 (0.58–1.39) | 0.89 (0.55–1.42) | 1 (ref) | 1.72 (1.10–2.72) | 1.77 (1.01–3.04) | 6.07 (3.70–9.89) |
| 1.11 (0.72–1.75) | 0.96 (0.59–1.55) | 1 (ref) | 1.61 (1.01–2.56) | 1.51 (0.84–2.63) | 4.33 (2.55–7.31) | |
# Adjusted for age, sex, Charlson comorbidities score, eGFR and principal diagnosis.
Fig 5Days of patient survival relating to Cl increase within 48 hours of admission.